Fig 1.
The flowchart of including and excluding literatures. (Flow Diagram).
Table 1.
Characteristics of the included trials.
Fig 2.
Serum phosphorus levels after 4 weeks (A) or 8 weeks (B) administration of calcium-based phosphate binders.
Fig 3.
Serum calcium levels after 8 weeks administration of calcium-based phosphate binders.
Fig 4.
Serum calcium by phosphorus (Ca x P) products after 8 weeks administration of calcium-based phosphate binders.
Fig 5.
Serum PTH levels after 8 weeks administration of calcium-based phosphate binders.
Fig 6.
The incidences of drug intolerance in calcium-based phosphate binder groups.
Fig 7.
The incidence of hypercalcaemia in calcium-based phosphate binder groups.
Fig 8.
Significant visual asymmetry was revealed by the funnel plots (A) and the visual asymmetry disappeared after excluding one study with unreasonable results (B).